Determining a specific clinical diagnosis can benefit a patient with infectious diarrhoea by:
Directing appropriate therapy
Allowing the judicious use of antimicrobial agents
Improving patient satisfaction
true
Gastrointestinal Infections Portfolio
Targeted molecular stool testing that decreases turnaround time, increases accuracy and aids in patient management
- Overview
BD offers targeted syndromic panels to address clinical need and optimise results
Because it can be difficult to differentiate the cause of gastrointestinal illness, targeted testing allows clinicians to accurately decide which tests are needed according to the patient’s clinical presentation and history.
The innovation of the BD MAX™ System offers you a fully integrated, automated real-time PCR platform with an array of targeted syndromic panels that provide improved rapid detection of bacterial, viral and parasitic pathogens responsible for ≥90% of infectious diarrhoea.1
Transitioning from culture to molecular testing, namely nucleic acid-based amplification tests (NAATs), has been shown to significantly improve the sensitivity, specificity, time to results of your laboratory’s gastroenteritis testing.2
When early detection or identification of pathogens can help lead to faster treatment decisions, reduce hospital length of stay, prevent unnecessary antibiotic use and most importantly, save lives, you need to implement the most rapid, reliable testing solution.3
HOW TARGETED TESTING CAN HELP YOU WITH GI DIAGNOSTIC CHALLENGES AND PATIENT MANAGEMENT
Infectious diarrhoea affects billions of people globally each year
~ 1.7 billion cases of children with infectious gastroenteritis each year4
Infectious diarrhoea is the 2nd leading cause of the death in children under 5 years of age4
Norovirus resulted in a total of $4.2 billion in direct health system costs5
The limitations of traditional methods (including culture, microscopy and immunoassay) include:
Delayed results6
Difficulty growing certain organisms on culture media7
False results due to subjective interpretation of microscopy8
Poor sensitivity and specificity with immunoassays9
BD’s focused syndromic approach provides the flexibility to optimise testing algorithms by selecting the most appropriate enteric panel(s) based on patient exposure, risk factors and clinical presentations.10
BD MAX™ Enteric Bacterial Panel
Salmonella spp.
Campylobacter spp. (C. jejuni and C. coli)
Shigella spp and EIEC
Shiga toxin (stx1/stx2) genes (found in STEC)
BD MAX™ Extended Enteric Bacterial Panel
Plesiomonas shigelloides
Vibrio spp. (V. vulnuficus, V. parahaemo lyticus, V. cholerae)
Enterotoxigenic E. coli (ETEC)
Yersinia entercolitica
BD MAX™ Enteric Parasite Panel
Giardia lamblia
Cryptosporidium spp (C. hominis and C. parvum)
Entamoeba histolytica
BD MAX™ Enteric Viral Panel
Norovirus GI & GII
Rotavirus A
Adenovirus F40/41
Sapovirus (genogroups I, II, IV, V)
Human Astrovirus (hAstro
BD MAX™ Enteric Viral Panel-NR
Norovirus GI & GII
Rotavirus A
Contact us
to discuss how we can support
your enteric testing needs
Email us at advancingdiagnostics@bd.com
EIEC, Enteroinvasive Escherichia coli; ETEC, Enterotoxigenic Escherichia coli; STEC, Shiga toxin–producing Escherichia coli.
Shigella dysenteriae can possess a Shiga toxin gene identical to the Shiga toxin 1 found in STEC.
BD, the BD Logo, BD MAX are trademarks of Becton, Dickinson and Company or its affiliates. © 2023 BD. All rights reserved.
The BD MAX™ System, BD MAX™ Enteric Bacterial & Extended Enteric Bacterial Panels, BD MAX™ Enteric Viral Panel, BD MAX™ Enteric Viral Panel-NR, BD MAX™ Enteric Parasite Panel, BD MAX™ Vaginal Panel, BD MAX™ CPO, BD MAX™ MRSA XT, BD MAX™ StaphSR, BD MAX™ Cdiff, BD MAX™ MDR-TB, BD SARS-CoV-2 Reagents for BD MAX™ System, BD SARS-CoV-2/Flu for BD MAX™ System, BD Respiratory Viral Panel for BD MAX™ System, VIASURE SARS-CoV-2 (N1+N2) Real Time PCR Detection Kit for BD MAX™ System, VIASURE SARS-CoV-2 Variant Real Time PCR Detection Kit for BD MAX™, VIASURE SARS-CoV-2 Variant II Real Time PCR Detection Kit for BD MAX™, VIASURE SARS-CoV-2, Flu (A+B), RSV Real Time PCR Detection Kit for BD MAX™ System, VIASURE Flu A, Flu B & RSV Real Time PCR Detection Kit for BD MAX™ System, VIASURE VanR Real Time PCR Detection Kit for BD MAX™ System, VIASURE Pneumocystis jirovecci Real Time PCR Detection Kit for BD MAX™ System and VIASURE Bordetella Real Time PCR Detection Kit for BD MAX™ System are in vitro diagnostic medical devices bearing a CE mark.
The BD CTGC2 and BD CTGCTV2 assays for BD MAX™ System are in vitro diagnostic medical devices bearing a CE mark and are CE certified by BSI Group The Netherlands B.V. (Notified Body Number = 2797).
- Sidoti F, Ritta M, Costa C, et al. Diagnosis of viral gastroenteritis: limits and potential pf currently available procedures. J Infect Dev Ctries 2015;9:551-561
- Amjad M. An Overview of the Molecular Methods in the Diagnosis of Gastrointestinal Infectious Diseases. Int J Microbiol. 2020 Mar 24;2020:8135724. doi: 10.1155/2020/8135724
- NICE. BD MAX™ Enteric Bacterial Panel for Identifying Pathogens in Contagious Gastroenteritis Medtech Innovation Briefing.; 2015. www.nice.org.uk/guidance/mib32
- World Health Organization. Diarrhoeal disease. Available at: https://www.who.int/news-room/fact-sheets/detail/diarrhoeal-disease. Accessed May 2020.
- Bartsch et al. PLoS ONE. 2016;11(4):e0151219.
- Mortensen et al. BMC Clin Pathol. 2015;15:9.
- Anderson et al. J Clin Microbiol. 2014;52(4):1222-1224.
- Centers for Disease Control and Prevention. Parasites – Amebiasis – Entamoeba histolytica Infection. Available at: https://www.cdc.gov/parasites/amebiasis/index.html. Updated December 16, 2015. Accessed May 2020.
- Humphries R et al. Clin Microbiol Rev. 2015;28(1):3-31.
- Shane AL et al. Clin Infect Dis. 2017 Nov 29;65(12):e45-e80
true
